Sanofi’s MS Drug Fails Phase III Trial, While FDA Again Delays Approval Application

Sanofi’s multiple sclerosis hopeful tolebrutinib faced dual setbacks on Monday, with a late-stage failure in one form of the disease and yet another regulatory setback in another.